Xeris Biopharma Holdings (XERS) Non-Current Deferred Tax Liability (2020 - 2024)

Xeris Biopharma Holdings has reported Non-Current Deferred Tax Liability for 5 years, with the latest figure at $3.3 million in Q2 2024.

• For the quarter ending Q2 2024, Non-Current Deferred Tax Liability rose 16.92% year-over-year to $3.3 million; the trailing twelve-month figure through Jun 2024 stood at $3.3 million (up 16.92% YoY), and the FY2023 full-year result was $2.3 million, down 37.57% from the prior year.
• Non-Current Deferred Tax Liability for Q2 2024 stood at $3.3 million, up from $2.6 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $5.3 million in Q4 2021, with the low at $442000.0 in Q4 2020.
• Historically, Non-Current Deferred Tax Liability has averaged $3.2 million across 5 years, with a median of $3.4 million in 2023.
• Annual changes were most pronounced in 2021 — Non-Current Deferred Tax Liability soared 1100.45% — and 2023, when it tumbled 37.57%.
• Xeris Biopharma Holdings' Non-Current Deferred Tax Liability stood at $442000.0 in 2020, then soared by 1100.45% to $5.3 million in 2021, then slumped by 31.53% to $3.6 million in 2022, then plunged by 37.57% to $2.3 million in 2023, then soared by 46.56% to $3.3 million in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at $3.3 million (Q2 2024), $2.6 million (Q1 2024), and $2.3 million (Q4 2023), per Business Quant data.